Nika BioTechnology Inc
Nika Pharmaceuticals, Inc., a pharmaceutical company, develops drugs for the treatment of HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes, and various other diseases. It offers dietary supplements and antiviral drugs, as well as thymus nuclear glycoprotein for the treatment of HIV. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika P… Read more
Nika BioTechnology Inc (NIKA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.036x
Based on the latest financial reports, Nika BioTechnology Inc (NIKA) has a cash flow conversion efficiency ratio of 0.036x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.33K) by net assets ($-260.54K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nika BioTechnology Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Nika BioTechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nika BioTechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nika BioTechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TFF Group
PINK:FRFTF
|
0.064x |
|
Keros Therapeutics Inc
NASDAQ:KROS
|
0.005x |
|
Blue Water Acquisition Corp. III Unit.
NASDAQ:BLUWU
|
-0.001x |
|
LUXFER HLDGS PLC LS-50
F:LX4A
|
N/A |
|
Qingdao Greensum Ecology Co. Ltd.
SHE:300948
|
N/A |
|
Zilltek Technology Corp
TWO:6679
|
0.028x |
|
Suzhou W Deane New Power Elec
SHG:603312
|
0.065x |
|
Miracll Chemicals Co Ltd
SHE:300848
|
0.055x |
Annual Cash Flow Conversion Efficiency for Nika BioTechnology Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Nika BioTechnology Inc from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-221.23K | $-154.93K | 0.700x | -11.26% |
| 2023-12-31 | $-82.15K | $-64.83K | 0.789x | -59.47% |
| 2022-12-31 | $-17.32K | $-33.72K | 1.947x | +212.58% |
| 2021-12-31 | $-23.62K | $-14.71K | 0.623x | -37.71% |
| 2020-12-31 | $-8.91K | $-8.91K | 1.000x | -- |